loading
前日終値:
$39.97
開ける:
$40.14
24時間の取引高:
3.98M
Relative Volume:
0.73
時価総額:
$48.40B
収益:
$17.53B
当期純損益:
$1.58B
株価収益率:
30.84
EPS:
1.3457
ネットキャッシュフロー:
$444.18M
1週間 パフォーマンス:
+3.21%
1か月 パフォーマンス:
+4.25%
6か月 パフォーマンス:
+17.30%
1年 パフォーマンス:
+105.14%
1日の値動き範囲:
Value
$40.01
$41.67
1週間の範囲:
Value
$39.10
$40.86
52週間の値動き範囲:
Value
$19.23
$42.02

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name
名前
Teva Pharmaceutical Industries Ltd Adr
Name
セクター
Healthcare (1052)
Name
電話
972 (3) 914-8213
Name
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Name
職員
33,346
Name
Twitter
@TevaUSA
Name
次回の収益日
2026-11-03
Name
最新のSEC提出書
Name
TEVA's Discussions on Twitter

Compare TEVA vs TAK, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
41.50 48.40B 17.53B 1.58B 444.18M 1.3457
TAK icon
TAK
Takeda Pharmaceutical Co Adr
19.98 63.83B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
8.595 37.80B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
78.65 32.50B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
592.88 25.43B 3.17B 1.29B 1.01B 27.09

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-01 開始されました TD Cowen Buy
2026-09-23 開始されました Oppenheimer Outperform
2026-09-09 開始されました Leerink Partners Outperform
2025-12-09 開始されました Barclays Overweight
2025-12-05 開始されました Scotiabank Sector Outperform
2025-06-06 開始されました Goldman Buy
2025-05-28 開始されました Truist Buy
2025-05-12 アップグレード JP Morgan Neutral → Overweight
2024-07-10 アップグレード Argus Hold → Buy
2024-03-08 アップグレード JP Morgan Underweight → Neutral
2024-02-12 アップグレード Piper Sandler Neutral → Overweight
2024-01-23 アップグレード Jefferies Hold → Buy
2024-01-03 アップグレード Piper Sandler Underweight → Neutral
2023-12-18 開始されました HSBC Securities Buy
2023-11-27 アップグレード UBS Neutral → Buy
2023-07-06 アップグレード UBS Sell → Neutral
2023-05-25 開始されました Morgan Stanley Equal-Weight
2023-05-18 アップグレード Evercore ISI In-line → Outperform
2023-01-19 ダウングレード Jefferies Buy → Hold
2022-11-14 ダウングレード JP Morgan Neutral → Underweight
2022-11-04 ダウングレード UBS Neutral → Sell
2022-10-21 再開されました Jefferies Buy
2022-08-05 アップグレード BofA Securities Neutral → Buy
2022-06-14 再開されました UBS Neutral
2022-05-17 アップグレード BofA Securities Underperform → Neutral
2022-05-04 ダウングレード Piper Sandler Neutral → Underweight
2022-04-05 アップグレード Barclays Equal Weight → Overweight
2022-03-25 アップグレード Bernstein Mkt Perform → Outperform
2022-01-27 ダウングレード Argus Buy → Hold
2021-10-28 ダウングレード Raymond James Outperform → Mkt Perform
2021-05-04 ダウングレード UBS Buy → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2020-11-25 開始されました Oppenheimer Perform
2020-08-06 アップグレード Barclays Underweight → Equal Weight
2020-07-27 再開されました Goldman Neutral
2020-06-01 アップグレード SunTrust Hold → Buy
2020-04-24 再開されました Citigroup Neutral
2020-04-06 アップグレード UBS Neutral → Buy
2020-02-24 ダウングレード Edward Jones Hold → Sell
2019-11-12 アップグレード JP Morgan Underweight → Neutral
2019-10-17 アップグレード Gabelli & Co Hold → Buy
2019-08-07 ダウングレード Evercore ISI Outperform → In-line
2019-07-19 開始されました Wolfe Research Peer Perform
2019-07-15 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-07-10 再開されました Credit Suisse Neutral
2019-07-05 アップグレード Argus Hold → Buy
2019-06-11 開始されました Barclays Underweight
2019-06-03 アップグレード Oppenheimer Perform → Outperform
2019-05-30 ダウングレード BofA/Merrill Buy → Underperform
2019-05-28 ダウングレード UBS Buy → Neutral
2019-03-20 開始されました SunTrust Hold
2019-03-07 再開されました UBS Buy
すべてを表示

Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース

pulisher
Oct 27, 2026

Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin - Pharmaceutical Executive

Oct 27, 2026
pulisher
Oct 27, 2026

Fourteen brokerages set USD 46.08 target for Teva stock - ad-hoc-news.de

Oct 27, 2026
pulisher
Oct 27, 2026

Teva Pharmaceutical Industries (TEVA) Expected to Release Quarterly Earnings on Tuesday - MarketBeat

Oct 27, 2026
pulisher
Oct 27, 2026

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline - GlobeNewswire

Oct 27, 2026
pulisher
Oct 27, 2026

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline - Stock Titan

Oct 27, 2026
pulisher
Oct 27, 2026

Teva reports 44-week duvakitug data for Teva stock - ad-hoc-news.de

Oct 27, 2026
pulisher
Oct 26, 2026

Teva's Austedo-Led Turnaround Faces A Margin Test As Generics Drag On Third-Quarter Results - Finviz

Oct 26, 2026
pulisher
Oct 26, 2026

Zacks downgrades Teva stock to Strong Sell below yearly high - ad-hoc-news.de

Oct 26, 2026
pulisher
Oct 26, 2026

Is Teva Pharmaceutical Industries (TEVA) Still Undervalued Following Its Recent Pullback? - Simply Wall Street

Oct 26, 2026
pulisher
Oct 26, 2026

Piper Sandler sets USD 44.00 target for Teva stock ahead of results - ad-hoc-news.de

Oct 26, 2026
pulisher
Oct 26, 2026

Baron Health Care Fund Q3 2026 Top Contributors And Detractors - Seeking Alpha

Oct 26, 2026
pulisher
Oct 25, 2026

Where Will Neurocrine Biosciences Be in 5 Years? - The Motley Fool

Oct 25, 2026
pulisher
Oct 24, 2026

Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance

Oct 24, 2026
pulisher
Oct 23, 2026

Teva stock: At 4.31 percent below its high, Teva stock traded at USD 40.21 on October 22 - ad-hoc-news.de

Oct 23, 2026
pulisher
Oct 23, 2026

Teva reports Uvakitug efficacy data. November 3 results matter for Teva stock - ad-hoc-news.de

Oct 23, 2026
pulisher
Oct 22, 2026

Teva reports 44-week data: What it means for Teva Pharmaceutical Industries stock - AD HOC NEWS

Oct 22, 2026
pulisher
Oct 22, 2026

Teva (TEVA) Stock Looks Cheap Even After A 378% Run - Simply Wall Street

Oct 22, 2026
pulisher
Oct 21, 2026

Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial - Clinical Trials Arena

Oct 21, 2026
pulisher
Oct 21, 2026

Active Pharmaceutical Ingredients Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com

Oct 21, 2026
pulisher
Oct 21, 2026

Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial - Yahoo Finance

Oct 21, 2026
pulisher
Oct 21, 2026

Tetracyclines Market Research Reveals Strong 3.2% CAGR Outlook Through 2030 - openPR.com

Oct 21, 2026
pulisher
Oct 21, 2026

Teva reports 44-week duvakitug data and Barclays targets Teva stock at USD 47.00 - AD HOC NEWS

Oct 21, 2026
pulisher
Oct 21, 2026

Albuterol Market Report Provides Insights Into Market Evolution And Growth Prospects - openPR.com

Oct 21, 2026
pulisher
Oct 20, 2026

Teva Pharmaceutical Industries Limited (TEVA) Latest Press Releases & Corporate News - Yahoo Finance

Oct 20, 2026
pulisher
Oct 20, 2026

UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease - Investing News Network

Oct 20, 2026
pulisher
Oct 20, 2026

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term - GlobeNewswire

Oct 20, 2026
pulisher
Oct 19, 2026

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.

Oct 19, 2026
pulisher
Oct 19, 2026

Teva stock: At USD 41.29, Teva stock sits 1.74 percent below its 52-week high - ad-hoc-news.de

Oct 19, 2026
pulisher
Oct 18, 2026

Teva Pharmaceutical Industries (TEVA) Gets FDA Nod For Monthly Schizophrenia Injection - Simply Wall Street

Oct 18, 2026
pulisher
Oct 17, 2026

Stryker, Viatris, Flo, Teva, J&J: This Week in Healthcare - Healthcare Digital

Oct 17, 2026
pulisher
Oct 16, 2026

Inside Teva's Weltruza launch and Novo's GLP-1 strategy - Fierce Pharma

Oct 16, 2026
pulisher
Oct 16, 2026

Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR - GlobeNewswire Inc.

Oct 16, 2026
pulisher
Oct 16, 2026

Mayne Settles US Patent Suit With Teva Over Generic Imvexxy - Law360

Oct 16, 2026
pulisher
Oct 15, 2026

Mayne Pharma clears another legal hurdle as Teva agrees to 2032 generic entry for Imvexxy - Business News Australia

Oct 15, 2026
pulisher
Oct 15, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Given New $47.00 Price Target at Barclays - MarketBeat

Oct 15, 2026
pulisher
Oct 14, 2026

Cash per share of Teva Pharmaceutical Industries Limited – BIVA:TEVA1/N - TradingView

Oct 14, 2026
pulisher
Oct 13, 2026

Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360

Oct 13, 2026
pulisher
Oct 13, 2026

Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News

Oct 13, 2026
pulisher
Oct 13, 2026

J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView

Oct 13, 2026
pulisher
Oct 12, 2026

Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative

Oct 12, 2026
pulisher
Oct 12, 2026

Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.

Oct 12, 2026
pulisher
Oct 12, 2026

Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire

Oct 12, 2026
pulisher
Oct 12, 2026

Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire

Oct 12, 2026
pulisher
Oct 12, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat

Oct 12, 2026
pulisher
Oct 12, 2026

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 12, 2026

Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital

Oct 12, 2026
pulisher
Oct 12, 2026

Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView

Oct 12, 2026
pulisher
Oct 11, 2026

Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView

Oct 11, 2026

Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Teva Pharmaceutical Industries Ltd Adr (TEVA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
MIGNONE ROBERTO
Director
Sep 18 '26
Sale
39.06
367,600
14,356,802
0
Bridger Management, LLC (1)
Shareholder
Sep 18 '26
Proposed Sale
39.19
367,600
14,406,244
0
Savage Brian
Officer
Sep 18 '26
Proposed Sale
38.85
7,028
273,062
0
Savage Brian
Interim Chief Legal Officer
Sep 18 '26
Sale
38.85
7,342
285,215
8,500
Satchi-Fainaro Ronit
Director
Aug 21 '26
Sale
37.25
415
15,459
111,986
Weiss Amir
Chief Accounting Officer
Aug 21 '26
Option Exercise
19.61
2,500
49,025
15,571
Weiss Amir
Chief Accounting Officer
Aug 21 '26
Sale
37.62
9,445
355,301
13,071
Lippman Evan
EVP, Business Development
Aug 17 '26
Sale
36.57
18,600
680,291
25,591
Lippman Evan
Officer
Aug 17 '26
Proposed Sale
36.57
18,600
680,291
0
Zaks Tal Zvi
Director
Aug 05 '26
Sale
34.87
17
593
73,247
HLN HLN
$8.595
price down icon 14.05%
TAK TAK
$19.98
price down icon 0.84%
ZTS ZTS
$78.65
price up icon 1.09%
$592.88
price up icon 1.09%
$19.18
price up icon 2.16%
$146.36
price up icon 0.57%
大文字化:     |  ボリューム (24 時間):